This CME activity is jointly sponsored by The Angiogenesis Foundation and The Institute for Medical Studies.

This activity is supported by an educational grant from Astra Zeneca and Pfizer, Inc.

---

ACCREDITATION STATEMENT

This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) thru the Joint Sponsorship of the Institute for Medical Studies (IMS) and the Angiogenesis Foundation. IMS is accredited by the ACCME to provide continuing medical education for physicians

CREDIT DESIGNATION

IMS designates this educational activity for a maximum of two (2) AMA PRA Category 1 Credits. Physicians should claim only those hours of credit that he/she spent in the educational activity.

Nurses may claim credit for activities approved for AMA PRA Category 1 Credits in most states, for up to 50% of the nursing requirement for recertification. This activity is designated for up to 2 hours of AMA PRA Category 1 Credits.

Release and Expiration Dates

The release date of this activity is December, 2007.
Credit is valid thru November, 2008.

INTENDED AUDIENCE

Practicing oncologists and oncology nurses in the US.

EDUCATIONAL OBJECTIVES

• Describe angiogenesis targets and pathways in cancer
• Describe the paradigm shifts in cancer management accompanying antiangiogenic therapy
• Review clinical data regarding the use of antiangiogenic agents in treating metastatic non-small cell lung cancer

METHOD OF PARTICIPATION

Review the illustrations on the corresponding wall chart, and then visit the website for additional content, CME registration and evaluation.

---

Faculty Disclosure

Alex Adjei, M.D., has no relationships to disclose that are germane to this CME activity.

Alan Sandler, M.D., has a financial interest/relationship of affiliation in the form of:

• Grants/research support from Genentech, Bristol-Myers Squibb, Eli Lily, Sanofi-Aventis, OSI, Pfizer, Bayer, Astra Zeneca, Amgen, Cyclocef, Wyeth
• Consultant to Genentech, Amgen, Bristol-Myers Squibb, Eli Lily, Sanofi-Aventis, OSI, Bayer, Astra Zeneca
• Speaker’s bureau for Genentech

Mark Socinski, M.D., has a financial interest/relationship or affiliation in the form of:

• Grants/research support from Genentech and Pfizer
• Speaker’s bureau for Pfizer

William Li, M.D.

• Has no relationships to disclose that are germane to this CME activity

Rod Smith, Medical Writer and Editor, The Angiogenesis Foundation

• Has no relationships to disclose that are germane to this CME activity

---

DISCUSSION OF UNLABELED USE

This CME activity contains discussion of published and/or investigational use of bevacizumab (Avastin), CP-751871, DMXAA (ASA404), MPC-6827, erlotinib (Tarceva), sorafenib (Nexavar), sunitinib (Sutent), vandetanib (ZD6474), and VEGF Trap (Aflibercept).